M&A Deal Summary

Predictive Oncology Acquires Soluble Therapeutics

On June 2, 2020, Predictive Oncology acquired life science company Soluble Therapeutics from CytoBioscience

Acquisition Highlights
  • This is Predictive Oncology’s 2nd transaction in the Life Science sector.
  • This is Predictive Oncology’s 2nd transaction in the United States.
  • This is Predictive Oncology’s 2nd transaction in Alabama.

M&A Deal Summary
Date 2020-06-02
Target Soluble Therapeutics
Sector Life Science
Buyer(s) Predictive Oncology
Sellers(s) CytoBioscience
Deal Type Divestiture

Target

Soluble Therapeutics

Birmingham, Alabama, United States
Soluble Therapeutics, Inc. specializes in the formulation optimization of protein-based therapeutics and vaccines on a contract basis for pharmaceutical, biotech, and vaccine companies.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Predictive Oncology

Eagan, Minnesota, United States
Category Company
Founded 2002
Sector Life Science
Employees34
Revenue 2M USD (2023)
DESCRIPTION

Predictive Oncology operates through three segments (Domestic, International, and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical, and Skyline Europe. Predictive Oncology was founded in 2002 and is based in Eagan, Minnesota.

DEAL STATS #
Overall 2 of 3
Sector (Life Science) 2 of 3
Type (Divestiture) 2 of 2
State (Alabama) 2 of 2
Country (United States) 2 of 3
Year (2020) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-06-02 BioDtech

Birmingham, Alabama, United States

BioDtech, Inc. develops and markets products for the detection, neutralization, and removal of biological toxins for pharmaceutical manufacturing and clinical applications. BioDtech was founded in 2003 and is based in Birmingham, Alabama.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-12-01 zPREDICTA

San Jose, California, United States

zPREDICTA develops tumor-specific in vitro models for oncology drug discovery and research. Its mission is to accelerate the drug development process for pharmaceutical clients and partners. Based on their proprietary models, zPREDICTA offers preclinical testing services to clients in the biopharmaceutical industry and through its partnership with a large pharma company. zPREDICTA was founded in 2014 and is based in San Jose, California.

Buy -

Seller(S) 1

SELLER

CytoBioscience

San Antonio, Texas, United States
Category Company
Sector Medical Products
DESCRIPTION

CytoBioscience, Inc. is a manufacturer of devices that represent a convergence of bioscience, nano science, microchip development, algorithms and engineering.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Divestiture) 2 of 2
State (Alabama) 2 of 2
Country (United States) 2 of 2
Year (2020) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-06-02 BioDtech

Birmingham, Alabama, United States

BioDtech, Inc. develops and markets products for the detection, neutralization, and removal of biological toxins for pharmaceutical manufacturing and clinical applications. BioDtech was founded in 2003 and is based in Birmingham, Alabama.

Sell -
Mergr

Product

Company

Legal